LaunchTrends: Keytruda (Wave 2) is the second in a series of syndicated reports designed to track the physician perception, uptake, and competitive environment of the malignant melanoma drug Keytruda (Merck & Co.’s pembrolizumab).

LaunchTrends: Keytruda measures the impact of this novel agent on the unresectable or metastatic malignant melanoma therapy market following launch, based on a blend of quantitative and qualitative primary research with U.S. medical oncologists. The report evaluates physicians’ current awareness and perception of Keytruda relative to other currently available therapies for unresectable or metastatic malignant melanoma, current and anticipated use of Keytruda, and promotional activity of Keytruda. Wave 2 also assesses surveyed medical oncologists’ perceptions of Opdivo (Bristol-Myers Squibb’s nivolumab) following its approval for the treatment of malignant melanoma in December 2014.

Questions Answered:

  • What is the awareness of and familiarity with Keytruda among medical oncologists?
  • What are the perceived clinical advantages and disadvantages of Keytruda compared with other marketed agents used for treating unresectable or metastatic malignant melanoma?
  • To what extent is Keytruda currently being used by surveyed medical oncologists? Where does Keytruda fit in the treatment algorithm? What reasons do nonprescribers give for not having prescribed Keytruda?
  • What promotional messages are being employed by Merck & Co. for Keytruda?

Scope: 

Markets covered: United States.

Primary research: 78 medical oncologists; qualitative interviews with 10 respondents.

Indication coverage: unresectable or metastatic malignant melanoma.

Table of contents

  • Keytruda Launch Tracking (US) Wave 2
    • Key Findings
      • Awareness and Perceptions of Keytruda
      • Keytruda Trial and Use
      • Competitive Landscape and Merck & Co.'s Promotion of Keytruda
    • Benchmarking Keytruda Launch Success vs. Malignant Melanoma and NSCLC Analogues
    • Prescriber and Nonprescriber Profiles
    • Keytruda Awareness and Perceptions
      • Unaided and Aided Awareness of Keytruda
        • Aided Awareness and Level of Familiarity with Keytruda
        • Unaided Awareness of Drugs for the Treatment of Unresectable or Metastatic Melanoma
        • Awareness of Keytruda's Indication/Setting
        • Awareness of Keytruda's Recommended Dosing Schedule
        • Awareness of Keytruda's Price
        • Aided Awareness and Level of Familiarity with Opdivo
      • Familiarity with Keytruda
        • Familiarity with Drugs for the Treatment of Unresectable or Metastatic Melanoma
        • Level of Familiarity with Keytruda Data
        • Level of Familiarity with Opdivo Data
      • Sources of Familiarity with Keytruda
      • Initial Reaction to and Interest in Keytruda
      • Impressions of Keytruda
        • Perception of Keytruda's Risk-Benefit Profile and Uniqueness
        • Perceived Advantages and Disadvantages of Keytruda Compared with Currently Available Treatment Options
        • Perception of Opdivo's Risk-Benefit Profile and Uniqueness
    • Keytruda Trial and Use
      • Willingness to Prescribe Keytruda
      • Number of Patients Currently Receiving Keytruda
        • Therapies Used for BRAF Wild-Type Unresectable or Metastatic Melanoma Patients (Wave 2)
        • Therapies Used for BRAF-Mutation-Negative (Wild Type), Unresectable or Metastatic Melanoma Patients
        • Therapies Used for BRAF-Mutation-Positive, Unresectable or Metastatic Melanoma Patients (Wave 1)
        • Impact of Keytruda and Opdivo on Prescription of Other Agents for BRAF-Mutation-Positive, Unresectable or Metastatic Patients
        • Therapies Used for BRAF-Mutation-Positive, Unresectable or Metastatic Melanoma Patients (Wave 2)
        • Impact of Keytruda and Opdivo on Prescription of Other Agents for BRAF Wild-Type Unresectable or Metastatic Patients (Wave 1)
        • Off-Label Use of Keytruda
        • Off-Label Use of Keytruda Among Patient Populations
        • Patient Experience with Keytruda
        • Off-Label Use of Opdivo
        • Current Treatment of Unresectable or Metastatic Melanoma
      • Reasons for Not Yet Prescribing Keytruda
        • Key Reasons to Choose Another Agent Over Keytruda
      • Anticipated Keytruda Use
        • Therapies Most Likely to Be Prescribed to Unresectable or Metastatic Melanoma Patients in Different Treatment Scenarios (Wave 2)
        • Willingness to Prescribe Keytruda in Treatment-Naive Patients
        • Patient Inquiries and Requests Regarding Keytruda
        • Expected Prescribing of Keytruda Among Current Nonprescribers
        • Expected Prescribing of Opdivo Among Current Nonprescribers
        • Potential Settings for Keytruda: Future line extensions
      • Keytruda Performance on Key Attributes
        • Overall Satisfaction with Keytruda
        • Satisfaction with Keytruda's Efficacy
        • Satisfaction with Keytruda's Safety and Tolerability
        • Competitive Landscape
        • Keytruda Attribute Importance and Performance
        • Performance of Keytruda vs. Opdivo
        • Factors Constraining Keytruda's Adoption
        • Overall Satisfaction with Opdivo
        • Satisfaction with Opdivo's Efficacy
        • Satisfaction with Opdivo's Safety and Tolerability
        • Factors Constraining Opdivo's Adoption
    • Effectiveness of Face-to-Face Detailing for Keytruda
      • Keytruda Sales Representative Frequency and Reach
        • Qualitative Quotes
      • Satisfaction with Keytruda Sales Representative
      • Keytruda Message Recall
    • Methodology
      • Primary Market Research Methodology
      • Physician Demographics
    • Appendix
      • Primary Market Research
        • Competitive Landscape (Wave 1)
        • Importance of Attributes in Influencing Prescribing Decisions (Wave 1)
        • Importance of Attributes in Influencing Prescribing Decisions (Wave 2)
        • Performance of Keytruda (Wave 1)
        • Performance of Keytruda (Wave 2)
        • Therapies Most Likely to Be Prescribed to Unresectable or Metastatic Melanoma Patients in Different Treatment Scenarios (Wave 1)
        • Therapies Most Likely to Be Prescribed to Second-Line BRAF-Mutation-Positive, Unresectable or Metastatic Melanoma Patients (Wave 1)
      • Additional Information
        • Coordination of Keytruda Dosing Schedules
        • Managed Care
        • Case Studies
        • Background, Market News, Methodology, and Objectives

Author(s): Rachel Webster

Rachel Webster , is a senior director in the oncology and biosimilars team at Decision Resources Group, where she manages a team of analysts in producing syndicated primary and secondary market research reports on a wide range of oncology indications. She also provides sales and client support for all oncology products. Previously, Dr. Webster was a senior analyst in the oncology group at Decision Resources. Dr. Webster has extensive experience in market forecasting with detailed expertise in cancer immunotherapies, prostate cancer, gastric cancer, and malignant melanoma. Dr Webster is also experienced in conducting primary research with physicians and payers in a wide range of oncology indications across the major pharmaceutical markets. Prior to joining Decision Resources Group, Dr. Webster was a research scientist at Immunocore in the target validation group, where her research focused on identifying target antigens expressed in cancers and autoimmune diseases using a proprietary T-cell receptor (TCR) technology platform, molecular biology and phage display techniques. Dr. Webster obtained her , in biochemistry, and (Hons) in biological sciences, from the University of Oxford.


Related Reports

Malignant Melanoma | Unmet Need | Detailed, Expanded Analysis: BRAF-Mutation-Positive, Unresectable or Metastatic Malignant Melanoma

Treatment of BRAF-mutation-positive unresectable or metastatic malignant mel...

View Details

Malignant Melanoma | Landscape & Forecast | Disease Landscape & Forecast

Although the malignant melanoma market has become increasingly crowded, an evolving trend of combining drug classes to create novel therapies is expanding treatment options for patients. While bo...

View Details